Evidence map›Paper›PMID 37218549›Full record

ArticleJournal of cachexia, sarcopenia and muscle2023

Five-year follow-up study on quantitative muscle magnetic resonance imaging in facioscapulohumeral muscular dystrophy: The link to clinical outcome.

Sanne C C Vincenten, Karlien Mul, Daniël van As, Julia J Jansen, Linda Heskamp, Arend Heerschap, Baziel G M van Engelen, Nicol C Voermans

Open access · goldAbstract read
In one paragraph

Article in Journal of cachexia, sarcopenia and muscle, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 20 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Observational
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Observational
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Sanne C C VincentenDonders Institute for Brain, Cognition and Behavior; Department of Neurology, Radboud University Medical Center, Nijmegen, The Netherlands.ORCID 0000-0002-0412-0670
Karlien MulDonders Institute for Brain, Cognition and Behavior; Department of Neurology, Radboud University Medical Center, Nijmegen, The Netherlands.
Daniël van AsDonders Institute for Brain, Cognition and Behavior; Department of Neurology, Radboud University Medical Center, Nijmegen, The Netherlands.
Julia J JansenDonders Institute for Brain, Cognition and Behavior; Department of Neurology, Radboud University Medical Center, Nijmegen, The Netherlands.
Linda HeskampDepartment of Medical Imaging (766), Radboud University Medical Center, Nijmegen, The Netherlands.
Arend HeerschapDepartment of Medical Imaging (766), Radboud University Medical Center, Nijmegen, The Netherlands.
Baziel G M van EngelenDonders Institute for Brain, Cognition and Behavior; Department of Neurology, Radboud University Medical Center, Nijmegen, The Netherlands.
Nicol C VoermansDonders Institute for Brain, Cognition and Behavior; Department of Neurology, Radboud University Medical Center, Nijmegen, The Netherlands.
Allen Institute for Brain Science · USRadboud University Nijmegen · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIt is unclear how changes in quantitative muscle magnetic resonance imaging (MRI) relate to changes in clinical outcome in facioscapulohumeral muscular dystrophy (FSHD), although this information is crucial for optimal use of MRI as imaging biomarker in trials. We therefore assessed muscle MRI and clinical outcome measures in a large longitudinal prospective cohort study.

methodsAll patients were assessed by MRI at baseline and at 5-year follow-up, employing 2pt-Dixon and turbo inversion recovery magnitude (TIRM) sequences, after which fat fraction and TIRM positivity of 19 leg muscles were determined bilaterally. The MRI compound score (CoS) was defined as the mean fat fraction of all muscles weighted for cross-sectional area. Clinical outcome measures included the Ricci-score, FSHD clinical score (FSHD-CS), MRC sumscore (MRC-SS), and motor-function-measure (MFM).

resultsWe included 105 FSHD patients [mean age 54 ± 14 years, median Ricci-score 7 (range 0-10)]. The median change over 5 years' time in the MRI-CoS was 2.0% (range -4.6 to +12.1; P < 0.001). The median change over 5 years' time in clinical outcome measures was small in all measures, with z-scores ranging from 5.0 to 7.2 (P < 0.001). The change in MRI-CoS correlated with change in FSHD-CS and Ricci-score (ρ = 0.25, respectively; ρ = 0.23, P < 0.05). The largest median increase in MRI-CoS was seen in baseline subgroups with an MRI-CoS 20-40% (6.1%), with ≥2 TIRM positive muscles (3.5%) or with an FSHD-CS 5-10 (3.1%).

conclusionsThis 5-year study showed significant changes in MRI and clinical outcome measures and a significant correlation between changes in MRI-CoS and changes in clinical outcome measures. In addition, we identified subgroups of patients that are most prone to radiological disease progression. This knowledge further establishes quantitative MRI parameters as prognostic biomarkers in FSHD and as efficacy biomarkers in upcoming clinical trials.

Indexed as

Muscular Dystrophy, FacioscapulohumeralAdultAgedBiomarkersFollow-Up StudiesHumansMagnetic Resonance ImagingMiddle AgedMuscle, SkeletalProspective StudiesBiomarkersBiomarkerClinical outcomeFSHDMRIMuscle imaging

Identifiers

PMID37218549
PMCPMC10401523
OpenAlexW4377564791

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.